In Endo's press release announcing FDA approval of the crush-resistant formulation of Opana ER, Dr. Endo sued the FDA three months later, hoping to hasten the agency's actions.Įndo's adamant plea to the FDA was prefaced by claims of increased patient safety with the crush-resistant formulation of Opana ER. The company strongly urged the FDA to keep the generic formulation of the original Opana ER off the market, citing a massive increase in abuse of Opana ER following the marketing of a crush-resistant formulation of Ox圜ontin. The Case For Fraud: Opana ERīelow is a timeline of the major events surrounding Endo and Opana ER.Įndo went through great lengths to prove that the old version of Opana ER was too dangerous for the market, but not before marketing the new, crush-resistant formulation for nearly a year. The company complied with the FDA's historical request for removal from the market of Endo's oxymorphone-based Opana ER in June of last year. Thus far, Endo has not admitted any wrongdoing and has appeared cooperative in the very early stages of litigation. Endo said it will cooperate in giving the requested information in the subpoena.Įach lawsuit claims that Endo used fraudulent marketing and falsified research surrounding the addictive properties of their oxymorphone based drug, Opana ER, in order to drive sales. Most recently, the Southern District of Florida filed a grand jury subpoena demanding Endo's "documents & information relating to products containing oxymorphone". Over ten states, cities, and counties have already filed lawsuits against the company, with more likely to come. Opioid LitigationĮndo Pharmaceuticals is facing litigation from counties and states all over the nation. Investors should refrain from going long on Endo until there is a better indication of the outcome of the lawsuits. Endo stands out amongst the other pharmaceutical companies being sued, and is much more likely to face detrimental consequences. Endo Pharmaceuticals ( ENDP) rapidly became a primary target of litigation filed by over a dozen U.S.
0 Comments
Leave a Reply. |